Composition Comprising Methylphenidate and Another Drug

Abstract

A process of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with P 450 metabolism wherein the methylphenidate is d-threo-methylphenidate.

1 . A method of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug, wherein said therapy is for attention-deficit hyperactivity disorder and said method provides for reduced side effects or reduced potential for abuse relative to racemic methylphenidate, said method comprising administering an effective amount of d-threo-methylphenidate to said subject daily.  
     
     
         2 . The method according to  claim 1 , wherein said d-threo-methylphenidate and said another drug is formulated for administration to an adult patient.  
     
     
         3 . The method according to  claim 1 , wherein the dosage of d-threo-methylphenidate administered to said subject is 5 mg to 60 mg.  
     
     
         4 . The method according to  claim 1 , wherein said d-threo-methylphenidate is in at least 95% enantiomeric excess relative to l-threo-methylphenidate.  
     
     
         5 . A method for treating a patient having a condition susceptible to treatment with methylphenidate and also exhibiting or likely to exhibit other central nervous system disorders, wherein said condition is attention-deficit disorder or attention-deficit hyperactivity disorder and said method provides for reduced side effects or reduced potential for abuse relative to racemic methylphenidate, said method comprising administering an effective amount of d-threo-methylphenidate to said patient daily.  
     
     
         6 . The method according to  claim 5 , wherein the dosage of d-threo-methylphenidate administered to said patient is 5 mg to 60 mg.  
     
     
         7 . The method according to  claim 5 , wherein said d-threo-methylphenidate is in at least 95% enantiomeric excess relative to l-threo-methylphenidate.  
     
     
         8 . A method for treating a patient having a condition that is susceptible to treatment with methylphenidate and concomitant therapy with another drug, wherein said condition is attention-deficit disorder or attention-deficit hyperactivity disorder and said method provides for reduced side effects or reduced potential for abuse relative to racemic methylphenidate, said method comprising administering an effective amount of d-threo-methylphenidate to said patient daily.  
     
     
         9 . The method according to  claim 8 , wherein the dosage of d-threo-methylphenidate administered to said patient is 5 mg to 60 mg.  
     
     
         10 . The method according to  claim 8 , wherein said d-threo-methylphenidate is in at least 95% eneantiomeric excess relative to --threo-methylphenidate.